Literature DB >> 16436702

Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome.

Mario Tumbarello1, Teresa Spanu, Maurizio Sanguinetti, Rita Citton, Eva Montuori, Fiammetta Leone, Giovanni Fadda, Roberto Cauda.   

Abstract

Bloodstream infections caused by extended-spectrum-beta-lactamase (ESBL)-producing Klebsiella pneumoniae isolates are a major concern for clinicians, since they markedly increase the rates of treatment failure and death. One hundred forty-seven patients with K. pneumoniae bloodstream infections were identified over a 5-year period (January 1999 to December 2003). The production of ESBLs in bloodstream isolates was evaluated by molecular methods. A retrospective case-case-control study was conducted to identify risk factors for the isolation of ESBL-producing K. pneumoniae or non-ESBL-producing K. pneumoniae isolates in blood cultures. Forty-eight cases infected with ESBL-producing K. pneumoniae isolates and 99 cases infected with non-ESBL-producing K. pneumoniae isolates were compared to controls. Risk factors for isolation of ESBL-producing K. pneumoniae isolates were exposure to antibiotic therapy (odds ratio [OR], 11.81; 95% confidence interval [CI], 2.72 to 51.08), age (OR, 1.14; 95% CI, 1.08 to 1.21), and length of hospitalization (OR, 1.10; 95% CI, 1.04 to 1.16). Independent determinants for isolation of non-ESBL-producing K. pneumoniae were previous urinary tract infection (OR, 8.50; 95% CI, 3.69 to 19.54) and length of hospitalization (OR, 1.07; 95% CI, 1.04 to 1.10). When the initial response was assessed at 72 h after antimicrobial therapy, the treatment failure rate for the ESBL-producing K. pneumoniae-infected group was almost twice as high as that of the non-ESBL-producing K. pneumoniae-infected group (31% versus 17%; OR, 2.19; 95% CI, 0.98 to 4.89). The 21-day mortality rate for all patients was 37% (54 of 147); it was 52% (25 of 48) for patients with ESBL-producing K. pneumoniae bloodstream infections and 29% (29 of 99) for patients with non-ESBL-producing K. pneumoniae bloodstream infections (OR, 2.62; 95% CI, 1.28 to 5.35). In summary, this investigation identifies epidemiological characteristics that distinguish ESBL-producing K. pneumoniae infections from non-ESBL-producing K. pneumoniae ESBL bloodstream infections.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16436702      PMCID: PMC1366869          DOI: 10.1128/AAC.50.2.498-504.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

Review 1.  Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review.

Authors:  A D Harris; T B Karchmer; Y Carmeli; M H Samore
Journal:  Clin Infect Dis       Date:  2001-03-21       Impact factor: 9.079

2.  Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.

Authors:  T Spanu; F Luzzaro; M Perilli; G Amicosante; A Toniolo; G Fadda
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Molecular characterization of extended-spectrum beta-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey.

Authors:  Mariagrazia Perilli; Emanuela Dell'Amico; Bernardetta Segatore; Maria Rosaria de Massis; Ciro Bianchi; Francesco Luzzaro; Gian Maria Rossolini; Antonio Toniolo; Giuseppe Nicoletti; Gianfranco Amicosante
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

Review 4.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

5.  Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region.

Authors:  P L Winokur; R Canton; J M Casellas; N Legakis
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

6.  Characterization of clinical isolates of Enterobacteriaceae from Italy by the BD Phoenix extended-spectrum beta-lactamase detection method.

Authors:  Maurizio Sanguinetti; Brunella Posteraro; Teresa Spanu; Daniela Ciccaglione; Lucio Romano; Barbara Fiori; Giuseppe Nicoletti; Stefania Zanetti; Giovanni Fadda
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

Review 7.  Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

Authors:  D L Paterson; W C Ko; A Von Gottberg; J M Casellas; L Mulazimoglu; K P Klugman; R A Bonomo; L B Rice; J G McCormack; V L Yu
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

8.  Extended-spectrum beta-lactamases: frequency, risk factors, and outcomes.

Authors:  Allison E Einhorn; Melinda M Neuhauser; David T Bearden; John P Quinn; Susan L Pendland
Journal:  Pharmacotherapy       Date:  2002-01       Impact factor: 4.705

9.  Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence.

Authors:  Gregory Bisson; Neil O Fishman; Jean Baldus Patel; Paul H Edelstein; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2002-05       Impact factor: 3.254

10.  Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection.

Authors:  John M Quale; David Landman; Patricia A Bradford; Melissa Visalli; Jayshree Ravishankar; Carlos Flores; David Mayorga; Kalyani Vangala; Adedeyo Adedeji
Journal:  Clin Infect Dis       Date:  2002-09-10       Impact factor: 9.079

View more
  71 in total

1.  Clinical characteristics of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type β-lactamases.

Authors:  Z A Qureshi; D L Paterson; A Y Peleg; J M Adams-Haduch; K A Shutt; D L Pakstis; E Sordillo; B Polsky; G Sandkovsky; M K Bhussar; Y Doi
Journal:  Clin Microbiol Infect       Date:  2011-09-26       Impact factor: 8.067

2.  Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.

Authors:  Mario Tumbarello; Maurizio Sanguinetti; Eva Montuori; Enrico M Trecarichi; Brunella Posteraro; Barbara Fiori; Rita Citton; Tiziana D'Inzeo; Giovanni Fadda; Roberto Cauda; Teresa Spanu
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

Review 3.  Clinical and economic impact of common multidrug-resistant gram-negative bacilli.

Authors:  Christian G Giske; Dominique L Monnet; Otto Cars; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

4.  Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients.

Authors:  D Averbuch; E Horwitz; J Strahilevitz; P Stepensky; N Goldschmidt; M E Gatt; M Y Shapira; I B Resnick; D Engelhard
Journal:  Infection       Date:  2013-05-08       Impact factor: 3.553

5.  Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system.

Authors:  Mario Tumbarello; Enrico Maria Trecarichi; Matteo Bassetti; Francesco Giuseppe De Rosa; Teresa Spanu; Eugenia Di Meco; Angela Raffaella Losito; Andrea Parisini; Nicole Pagani; Roberto Cauda
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

6.  Should we take into account ESBLs in empirical antibiotic treatment?

Authors:  Matteo Bassetti; Jesús Rodríguez-Baño
Journal:  Intensive Care Med       Date:  2016-10-21       Impact factor: 17.440

7.  Infections caused by multidrug resistant organisms are not associated with overall, all-cause mortality in the surgical intensive care unit: the 20,000 foot view.

Authors:  Laura H Rosenberger; Damien J LaPar; Robert G Sawyer
Journal:  J Am Coll Surg       Date:  2012-03-13       Impact factor: 6.113

8.  European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.

Authors:  Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

9.  Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004.

Authors:  Shawn R Lockhart; Murray A Abramson; Susan E Beekmann; Gale Gallagher; Stefan Riedel; Daniel J Diekema; John P Quinn; Gary V Doern
Journal:  J Clin Microbiol       Date:  2007-08-22       Impact factor: 5.948

Review 10.  The continuing challenge of ESBLs.

Authors:  Federico Perez; Andrea Endimiani; Kristine M Hujer; Robert A Bonomo
Journal:  Curr Opin Pharmacol       Date:  2007-09-17       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.